#1 Clinical Trials Search in Europe

Mps-102

This article explores clinical trials investigating the use of MPS-102, a component of the cancer vaccine OSE2101 (Tedopi), in various cancer types. OSE2101 is being studied as an immunotherapy treatment for non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 alone or in combination with other therapies.

Table of Contents

What is MPS-102?

MPS-102 is one of the active substances in TEDOPI, an experimental cancer vaccine being developed by OSE Immunotherapeutics[1]. TEDOPI contains 10 synthetically manufactured peptides, including MPS-102, that are designed to stimulate the immune system to fight cancer cells[2].

How Does MPS-102 Work?

As part of the TEDOPI vaccine, MPS-102 works by activating the body’s immune system to recognize and attack cancer cells. The vaccine is specifically designed for patients with a certain genetic profile called HLA-A2 positive[1]. This means it targets cancer cells in people whose immune systems have a specific type of molecule on their cells.

What Conditions is MPS-102 Being Studied For?

MPS-102, as part of the TEDOPI vaccine, is being studied for several types of cancer:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer[1].
  • Ovarian Cancer: Specifically for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy[3].
  • Pancreatic Cancer: For patients with locally advanced or metastatic pancreatic ductal adenocarcinoma[4].

Current Clinical Trials

There are several ongoing clinical trials evaluating TEDOPI (which includes MPS-102):

  • ARTEMIA Study: A phase 3 trial comparing TEDOPI to docetaxel in patients with advanced non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy[1].
  • TEDOVA Study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer[3].
  • TEDOPAM Study: A phase 2 trial studying TEDOPI plus FOLFIRI chemotherapy as a maintenance treatment for patients with advanced pancreatic cancer[4].

Potential Benefits

The potential benefits of MPS-102 as part of TEDOPI include:

  • Improved overall survival in patients with advanced cancers[1].
  • Potential for better quality of life compared to standard chemotherapy[3].
  • Possible option for patients who have developed resistance to other immunotherapy treatments[1].

Possible Side Effects

As TEDOPI is still in clinical trials, all potential side effects may not be known. However, common side effects of cancer vaccines can include:

  • Injection site reactions (redness, swelling, pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Immune-related adverse events (as with other immunotherapies)[3]

The safety profile is being closely monitored in all ongoing clinical trials[1][3][4].

Administration

TEDOPI, which contains MPS-102, is administered as a subcutaneous injection (an injection under the skin)[1]. The exact dosing schedule may vary depending on the specific clinical trial and condition being treated.

Trial Name Cancer Type Phase Main Objective Key Eligibility Criteria
ARTEMIA Metastatic Non-Small Cell Lung Cancer III Compare efficacy and safety of OSE2101 vs docetaxel HLA-A2 positive, secondary resistance to immune checkpoint inhibitors
OSE-279 Combination Advanced Solid Tumors or Lymphomas I/II Determine MTD/RP2D of OSE-279 alone and in combination with OSE2101 HLA-A2 positive for Part B and C, various tumor types
TEDOVA Platinum-sensitive Recurrent Ovarian Cancer II Evaluate PFS of OSE2101 alone or with pembrolizumab vs best supportive care HLA-A2 positive, controlled disease after platinum-based chemotherapy
TEDOPAM Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma II Assess OS of OSE2101 plus FOLFIRI vs FOLFIRI alone as maintenance therapy HLA-A2 positive, stable disease or response after FOLFIRINOX induction

FAQ

  • What is MPS-102? MPS-102 is one of the active substances in OSE2101 (Tedopi), an experimental cancer vaccine being studied as an immunotherapy treatment for various types of cancer.
  • What types of cancer are being studied with OSE2101? The clinical trials are investigating OSE2101 for non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer.
  • How is OSE2101 administered? OSE2101 is administered as an emulsion for injection, typically given subcutaneously (under the skin).
  • What are the main objectives of these clinical trials? The main objectives include assessing overall survival, progression-free survival, safety profiles, and tumor response rates in patients treated with OSE2101 alone or in combination with other therapies.
  • Who is eligible to participate in these trials? Eligibility varies by trial but generally includes adult patients with specific cancer types, adequate organ function, and certain HLA-A2 status. Detailed criteria are provided for each study.

Ongoing Clinical Trials on Mps-102

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • OSE2101 (Tedopi): An experimental cancer vaccine containing multiple synthetic peptides, including MPS-102, designed to stimulate the immune system to fight cancer cells.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) that is important for the immune system's ability to recognize and respond to certain cancer antigens. Many of the trials require patients to be HLA-A2 positive.
  • NSCLC: Non-small cell lung cancer, a type of lung cancer being studied in several of the clinical trials.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Platinum-sensitive: Refers to cancers that respond well to platinum-based chemotherapy treatments.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/